A Phase II, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Asthmatic Subjects Subsequently Challenged with Human Rhinovirus (HRV-16 [hVIVO])
Latest Information Update: 11 Jun 2019
At a glance
- Drugs Poly ICLC (Primary)
- Indications Rhinovirus infections
- Focus Therapeutic Use
- Sponsors hVIVO
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society
- 25 Sep 2017 Status changed from recruiting to completed.
- 06 Jun 2017 New trial record